Kori Ascher, DO
Pulmonary Disease · Miami, FLNPI 1083019749
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Harmony Biosciences LLC accounts for 86.9% of it on its own, with 9 other manufacturers making up the rest. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $380.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$43K
- Jazz Pharmaceuticals Inc.$6K
- Inspire Medical Systems, Inc.$249
- Axsome Therapeutics, Inc.$232
- Fisher & Paykel Healthcare Inc$106
- Resmed Corp$90
- plus $171 from 4 others
What the payments were for
- Consulting fees$18,42837%
- Speaking & faculty fees$24,86650%
- Travel & lodging$1,4063%
- Food & beverage$4,79010%
- Education$3801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 69 | $43,348 |
| Jazz Pharmaceuticals Inc. | 39 | $5,674 |
| Inspire Medical Systems, Inc. | 4 | $249 |
| Axsome Therapeutics, Inc. | 6 | $232 |
| Fisher & Paykel Healthcare Inc | 3 | $106 |
| Resmed Corp | 2 | $90 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $79 |
| Ambu Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,870 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 11 | $172 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.